{"id":1067956,"date":"2020-12-15T21:57:36","date_gmt":"2020-12-16T02:57:36","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/vtv-therapeutics-announces-topline-results-of-phase-2-elevage-study-of-azeliragon-in-patients-with-mild-alzheimers-disease-and-type-2-diabetes\/"},"modified":"2024-08-18T11:41:21","modified_gmt":"2024-08-18T15:41:21","slug":"vtv-therapeutics-announces-topline-results-of-phase-2-elevage-study-of-azeliragon-in-patients-with-mild-alzheimers-disease-and-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vtv-therapeutics-announces-topline-results-of-phase-2-elevage-study-of-azeliragon-in-patients-with-mild-alzheimers-disease-and-type-2-diabetes.php","title":{"rendered":"vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer\u2019s Disease and Type 2 Diabetes"},"content":{"rendered":"<p><![CDATA[HIGH POINT, N.C., Dec.  15, 2020  (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer\u2019s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer\u2019s Disease Assessment Scale \u2013 Cognitive Subscale (ADAS-cog14) relative to placebo. The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimer\u2019s disease and type 2 diabetes. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35. These differences were not statistically significant. Consistent with previous studies, azeliragon was generally well-tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups.]]><\/p>\n<p>Original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/12\/15\/2145823\/0\/en\/vTv-Therapeutics-Announces-Topline-Results-of-Phase-2-Elevage-Study-of-Azeliragon-in-Patients-with-Mild-Alzheimer-s-Disease-and-Type-2-Diabetes.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer\u2019s Disease and Type 2 Diabetes\">vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer\u2019s Disease and Type 2 Diabetes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Original post: vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer\u2019s Disease and Type 2 Diabetes <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/vtv-therapeutics-announces-topline-results-of-phase-2-elevage-study-of-azeliragon-in-patients-with-mild-alzheimers-disease-and-type-2-diabetes.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067956","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067956"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067956"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}